Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Net Income towards Common Stockholders: 2010-2024

Historic Net Income towards Common Stockholders for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$95.1 million.

  • Altimmune's Net Income towards Common Stockholders rose 16.77% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 18.82%. This contributed to the annual value of -$95.1 million for FY2024, which is 7.53% down from last year.
  • As of FY2024, Altimmune's Net Income towards Common Stockholders stood at -$95.1 million, which was down 7.53% from -$88.4 million recorded in FY2023.
  • Altimmune's 5-year Net Income towards Common Stockholders high stood at -$49.0 million for FY2020, and its period low was -$97.1 million during FY2021.
  • In the last 3 years, Altimmune's Net Income towards Common Stockholders had a median value of -$88.4 million in 2023 and averaged -$89.4 million.
  • Per our database at Business Quant, Altimmune's Net Income towards Common Stockholders plummeted by 133.85% in 2020 and then increased by 12.75% in 2022.
  • Over the past 5 years, Altimmune's Net Income towards Common Stockholders (Yearly) stood at -$49.0 million in 2020, then tumbled by 97.96% to -$97.1 million in 2021, then climbed by 12.75% to -$84.7 million in 2022, then declined by 4.41% to -$88.4 million in 2023, then declined by 7.53% to -$95.1 million in 2024.